Unlocking the Future of Personalized Medicine with iPS Cell Technology
I Peace, in Cooperation with SBI Holdings, Unveils Next-Gen Cell Mass-Manufacturing System “EGG” at SBI Holdings Inc. booth in the Osaka Healthcare Pavilion “Nest for Reborn” at the 2025 World Expo, Osaka
Excerpt from the Press Release:
PALO ALTO, Calif. , April 24, 2025 /PRNewswire/ — I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the next generation iPS cell mass-manufacturing automated system (EGG) the company has developed will be on display at the booth of SBI Holdings Inc., in the Osaka Healthcare Pavilion at 2025 World Expo, Osaka. iPS cell technology enables reprogramming your cells—regardless of your current age—back to a state similar to that of a fertilized egg. iPS cells, which share key properties with certain cells of fertilized eggs, have the potential to differentiate into a wide variety of cell types in the human body. They hold great promises for applications in regenerative medicine, drug discovery, and longevity science.
This innovative iPS cell manufacturing system “EGG” is capable of automatically creating not only iPS cells, but also various body cells made from iPS cells. This is the very first occasion where I Peace introduces this concept to the world. With clinical trials of iPS cell therapies conducted in various institutions around the world and the practical use of the iPS-derived cell therapies nearing, I Peace wishes to make a significant contribution to the further development of iPS cell therapies by improving the efficiency of iPS cell-derived cell differentiation. Our new mass-manufacturing automated system (EGG) enables efficient differentiated cell manufacturing by combining the two processes – iPS cell manufacturing and cell differentiation – into an automated single process with mass-manufacturing capability.
By utilizing “EGG”, we believe that by 2050, people around the world will be able to have their own cells and organs and even rejuvenate themselves using their own iPSC cells.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?